This inventor holds 1 USPTO granted patent. Top assignee: Dr. Reddy's Laboratories, Incorporated. Active years: 2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015
Title: **Bhanu Pratap Taduri: Innovator in Pharmaceutical Chemistry**
Introduction
Bhanu Pratap Taduri is an accomplished inventor based in Hanamkonda, India. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative processes in drug formulation. His work has led to the development of effective methods for creating essential medications.
Latest Patents
Bhanu Pratap Taduri holds one patent titled "Process for preparation of pure linagliptin." This patent discusses a detailed process involving the reaction of (R)-piperidine-3-amine with specific compounds in the presence of a suitable base and an inert organic solvent. This innovative method is crucial for producing linagliptin, a medication used in the treatment of type 2 diabetes.
Career Highlights
Currently, Bhanu Pratap Taduri works at Dr. Reddy's Laboratories, a well-respected company in the pharmaceutical industry. His role focuses on research and development, where he applies his knowledge to devise new approaches to medication preparation and improve existing processes.
Collaborations
Throughout his career, Bhanu has collaborated with notable colleagues such as Pranab Haldar and Venkateswarlu Muvva. These partnerships have fostered a dynamic environment for innovation and have contributed to the successful implementation of various projects within the company.
Conclusion
Bhanu Pratap Taduri's inventive spirit and dedication to pharmaceutical innovation have made him a notable figure in his field. With his patented process for linagliptin preparation, he continues to impact the lives of patients by contributing to the advancement of effective treatments. His collaborative efforts at Dr. Reddy's Laboratories further enhance the potential for future breakthroughs in the pharmaceutical sector.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
